Cargando…

Cancers prevented in Australia in 2010 through the consumption of aspirin

OBJECTIVES: To estimate the proportion and number of cancers in Australia in 2010 that may have been prevented from occurring due to daily use of aspirin in the population. METHODS: We calculated the Prevented Fraction (PF) of colorectal and oesophageal cancers using standard formulae. The PF is the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Louise F, Green, Adele C, Kendall, Bradley J, Jordan, Susan J, Nagle, Christina M, Bain, Christopher J, Neale, Rachel E, Whiteman, David C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606767/
https://www.ncbi.nlm.nih.gov/pubmed/26437724
http://dx.doi.org/10.1111/1753-6405.12443
_version_ 1782395418250838016
author Wilson, Louise F
Green, Adele C
Kendall, Bradley J
Jordan, Susan J
Nagle, Christina M
Bain, Christopher J
Neale, Rachel E
Whiteman, David C
author_facet Wilson, Louise F
Green, Adele C
Kendall, Bradley J
Jordan, Susan J
Nagle, Christina M
Bain, Christopher J
Neale, Rachel E
Whiteman, David C
author_sort Wilson, Louise F
collection PubMed
description OBJECTIVES: To estimate the proportion and number of cancers in Australia in 2010 that may have been prevented from occurring due to daily use of aspirin in the population. METHODS: We calculated the Prevented Fraction (PF) of colorectal and oesophageal cancers using standard formulae. The PF is the proportion of the hypothetical total load of cancer in the population that was prevented by exposure to aspirin. The formula incorporates estimates of the prevalence of aspirin use in Australian adult populations, the relative risks associated with aspirin use and cancer incidence. RESULTS: An estimated 335 colorectal cancers, 22 oesophageal adenocarcinomas and 29 oesophageal squamous cell carcinomas (SCC) were potentially prevented due to daily aspirin use. These figures equate to 2.2%, 3.1% and 5.4% of all colorectal cancers, oesophageal adenocarcinomas and oesophageal SCCs, respectively, that would otherwise have occurred but were potentially avoided due to the daily use of aspirin pertaining in the Australian population. CONCLUSIONS: At current levels of consumption, a small but measurable reduction in cancer incidence can be attributed to daily aspirin use. IMPLICATIONS: Assuming the benefits outweigh the harms of known gastrointestinal toxicity and other hazards, aspirin use may be considered for some people to prevent the development of particular gastrointestinal cancers.
format Online
Article
Text
id pubmed-4606767
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-46067672015-10-20 Cancers prevented in Australia in 2010 through the consumption of aspirin Wilson, Louise F Green, Adele C Kendall, Bradley J Jordan, Susan J Nagle, Christina M Bain, Christopher J Neale, Rachel E Whiteman, David C Aust N Z J Public Health Cancers in Australia in 2010 OBJECTIVES: To estimate the proportion and number of cancers in Australia in 2010 that may have been prevented from occurring due to daily use of aspirin in the population. METHODS: We calculated the Prevented Fraction (PF) of colorectal and oesophageal cancers using standard formulae. The PF is the proportion of the hypothetical total load of cancer in the population that was prevented by exposure to aspirin. The formula incorporates estimates of the prevalence of aspirin use in Australian adult populations, the relative risks associated with aspirin use and cancer incidence. RESULTS: An estimated 335 colorectal cancers, 22 oesophageal adenocarcinomas and 29 oesophageal squamous cell carcinomas (SCC) were potentially prevented due to daily aspirin use. These figures equate to 2.2%, 3.1% and 5.4% of all colorectal cancers, oesophageal adenocarcinomas and oesophageal SCCs, respectively, that would otherwise have occurred but were potentially avoided due to the daily use of aspirin pertaining in the Australian population. CONCLUSIONS: At current levels of consumption, a small but measurable reduction in cancer incidence can be attributed to daily aspirin use. IMPLICATIONS: Assuming the benefits outweigh the harms of known gastrointestinal toxicity and other hazards, aspirin use may be considered for some people to prevent the development of particular gastrointestinal cancers. John Wiley & Sons, Ltd 2015-10 2015-10-06 /pmc/articles/PMC4606767/ /pubmed/26437724 http://dx.doi.org/10.1111/1753-6405.12443 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Cancers in Australia in 2010
Wilson, Louise F
Green, Adele C
Kendall, Bradley J
Jordan, Susan J
Nagle, Christina M
Bain, Christopher J
Neale, Rachel E
Whiteman, David C
Cancers prevented in Australia in 2010 through the consumption of aspirin
title Cancers prevented in Australia in 2010 through the consumption of aspirin
title_full Cancers prevented in Australia in 2010 through the consumption of aspirin
title_fullStr Cancers prevented in Australia in 2010 through the consumption of aspirin
title_full_unstemmed Cancers prevented in Australia in 2010 through the consumption of aspirin
title_short Cancers prevented in Australia in 2010 through the consumption of aspirin
title_sort cancers prevented in australia in 2010 through the consumption of aspirin
topic Cancers in Australia in 2010
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606767/
https://www.ncbi.nlm.nih.gov/pubmed/26437724
http://dx.doi.org/10.1111/1753-6405.12443
work_keys_str_mv AT wilsonlouisef cancerspreventedinaustraliain2010throughtheconsumptionofaspirin
AT greenadelec cancerspreventedinaustraliain2010throughtheconsumptionofaspirin
AT kendallbradleyj cancerspreventedinaustraliain2010throughtheconsumptionofaspirin
AT jordansusanj cancerspreventedinaustraliain2010throughtheconsumptionofaspirin
AT naglechristinam cancerspreventedinaustraliain2010throughtheconsumptionofaspirin
AT bainchristopherj cancerspreventedinaustraliain2010throughtheconsumptionofaspirin
AT nealerachele cancerspreventedinaustraliain2010throughtheconsumptionofaspirin
AT whitemandavidc cancerspreventedinaustraliain2010throughtheconsumptionofaspirin